Azure, Continuous Integration & Continuous Delivery - CI/CD, Data science techniques, Data Transformation, DevOps, IT, Leadership Skill, Optimization, Python Programming, R Programming, SAS
You will be the main developer or possibly product owner for 1 or more products which are essential for operational data management, including search and data transformation. You should have systems analysis and expert programming experience in data engineering using at least one if not all of Python, R, and SAS, and eagerness to learn and use the others. You will be working on identified challenges to make them transparent, sketch out solutions, and implement prototypes which can be further developed into production platforms. The solutions are expected to be rapidly and incrementally delivered to the business using agile and scrum approaches. The solutions will be reviewed and refined as needed for use in related situations across the enterprise.
As a developer in the Data Office, you will the delivery of products in the data engineering domain which enable both the success of the UCB enterprise data strategy as well as the continual transformation necessary to achieve our UCB Data Ambitions. Is accountable along with product owners for managing the quality of product backlog items. Has experience with Azure DevOps software development and CI/CD approaches. Able to translate needs into software components and systems. Works in collaboration with the other Data Office staff to determine critical business programs to support to continuously drive next generation innovation and solution provisioning in the data domain.
Who you’ll work with
This role will partner with IT with the facilitation of the IT representative as well as with Data Scientists across the enterprise.
What you’ll do
Interested? For this role we’re looking for the following education, experience, and skills
Specific skills/competences
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease.
Walloon Brabant, Belgium
4-6 year